Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Research & Development (2018 - 2025)

IGC Pharma (IGC) has disclosed Research & Development for 8 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • Quarterly Research & Development rose 73.17% to $1.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Sep 2025, up 19.41% year-over-year, with the annual reading at $3.7 million for FY2025, 3.82% down from the prior year.
  • Research & Development for Q3 2025 was $1.6 million at IGC Pharma, up from $851000.0 in the prior quarter.
  • The five-year high for Research & Development was $1.6 million in Q3 2025, with the low at $276000.0 in Q3 2021.
  • Average Research & Development over 5 years is $843631.6, with a median of $852000.0 recorded in 2024.
  • The sharpest move saw Research & Development surged 304.26% in 2022, then plummeted 56.85% in 2023.
  • Over 5 years, Research & Development stood at $377000.0 in 2021, then soared by 113.79% to $806000.0 in 2022, then grew by 12.03% to $903000.0 in 2023, then fell by 5.65% to $852000.0 in 2024, then surged by 86.38% to $1.6 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.6 million, $851000.0, and $997000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.